Scientists find bacteria in pancreatic tumors that metabolize a common drug

Scientists find bacteria in pancreatic tumors that metabolize a common drug
Bacteria (green) inside human pancreatic cancer cells (AsPC-1 cells). The cells’ nuclei are stained blue while their cytoplasm is stained orange. Credit: Weizmann Institute of Science

To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic tumors. The findings further showed that some of these bacteria contain an enzyme that inactivates a common drug used to treat various cancers, including pancreatic cancer. Working with mouse models of cancer, they demonstrated how treatment with antibiotics on top of chemotherapy may be significantly superior to treatment with chemotherapy alone.

The research was conducted in the lab of Dr. Ravid Straussman of the Weizmann Institute of Science's Molecular Cell Biology Department, led by his graduate student Leore Geller and conducted in collaboration with Dr. Todd Golub and Dr. Michal Barzily-Rokini of the Broad Institute of the Massachusetts Institute of Technology. Many other collaborators supported different aspects of the study.

The the group found, explains Straussman, live within the tumors, and even within the cells. "Because the topic is so new, we first used different methods to prove that there really were bacteria inside the tumors. Then we decided to look at the effect that these bacteria might have on chemotherapy."

The researchers isolated bacteria from the tumors of cancer patients and tested how they affect the sensitivity of pancreatic cancer cells to gemcitabine, a chemotherapy . Indeed, some of those bacteria kept the drug from working. Further investigation showed that these bacteria metabolize the drug, making it ineffective. The researchers were able to find the bacterial gene responsible for this, a gene called cytidine deaminase (CDD). They demonstrated that CDD comes in two forms – a long and a short form. Only bacteria with the long form of the CDD gene could inactivate gemcitabine. The drug had no apparent effect on the bacteria.

The group examined over 100 human pancreatic tumors to show that these particular bacteria with long CDD do live in the patient's pancreatic tumors. They also used multiple methods to visualize the bacteria inside human pancreatic tumors. This is crucial, since bacterial contamination is a real issue for lab studies.

Oddly enough, it was an earlier incidence of bacterial contamination that led Straussman and his team to this present study. He and his group had been looking for evidence that normal cells in the cancer's environment contribute to chemotherapy resistance. While testing the effect of many normal, non-cancerous, human cells on the sensitivity of cancer cells to chemotherapy, they found a specific sample of normal that rendered pancreatic cancer cells resistant to gemcitabine. Tracking down the cause led the team to bacteria that had accidently contaminated these skin . "We nearly threw it away," says Straussman, "but then we decided to follow it up, instead." After revealing how these bacteria degraded the drug, he began to wonder if other bacteria might have a similar mechanism for inactivating the drug, and whether such bacteria might be found inside human tumors.

In the present study, further experiments in mouse models of cancer were done with two groups of bacteria: those containing the long form of the CDD gene and those in which the gene had been knocked out. Only the group with the CDD gene intact exhibited resistance when the drug was given to the mice. After treatment with antibiotics, this group also responded to the chemotherapy drug.

Many questions remain, and Straussman and his group are now asking whether bacteria may be found in other cancer types and, if so, what effects they might have on the cancer and its sensitivity to other anti-cancer drugs including a novel family of immune-mediated anti- drugs.


Explore further

Pancreatic cancer development

More information: Leore T. Geller et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, Science (2017). DOI: 10.1126/science.aah5043
Journal information: Science

Citation: Scientists find bacteria in pancreatic tumors that metabolize a common drug (2017, September 15) retrieved 23 October 2019 from https://medicalxpress.com/news/2017-09-scientists-bacteria-pancreatic-tumors-metabolize.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1376 shares

Feedback to editors

User comments

Sep 17, 2017
Bacteria causes cancer?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more